Last reviewed · How we verify
topical 1% methotrexate gel
At a glance
| Generic name | topical 1% methotrexate gel |
|---|---|
| Also known as | clobetasol propionate 0.05% ointment |
| Sponsor | Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Topical Methotrexate vs Minoxidil for Localized Alopecia Areata (PHASE4)
- Methotrexate Iontophoresis Versus Methotrexate 1% Gel on Depigmentation in Vitiligo Patients (NA)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Topical Methotrexate with Fractional CO2 Laser in Treatment of Non Segmental Vitiligo (NA)
- Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis (EARLY_PHASE1)
- The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo (PHASE3)
- Efficacy and Safety of Topical Methotrexate Gel 1% Coupled With Microneedling in Treatment of Warts (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: